araag2/HINT huggingface dataset:
Clinical trial NCT02111564 (phase 3, status: completed)
Conditions: heart failure, respiratory insufficiency, stroke acute, infectious diseases, rheumatic diseases
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0, H51.11, E27.1, E27.40, E27.49, I05.1, I06.1, I07.1, B99.8, B99.9, Z22.9, P37.9, B94.9, O98.92, O98.93, I09.9, I01.8, I01.9, I05.9, I06.9, I07.9, I08.9
Drugs: rivaroxaban, 10 mg, rivaroxaban, 7.5 mg, placebo
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  The duration of the index hospitalization must have been at least 3 and no more than
             10 consecutive days

          -  Must meet venous thromboembolism (VTE) risk criteria with a total modified Improve VTE
             Risk Score of: greater than or equal 4, or 3 with D-dimer > 2* upper limit of normal
             (ULN), or 2 with D-dimer > 2*ULN

        Key Exclusion Criteria:

          -  Any serious bleeding within 3 months prior to randomization or occurring during index
             hospitalization

          -  Serious trauma (including head trauma) within 4 weeks before randomization

          -  History of hemorrhagic stroke at any time in the past

          -  Any medical condition that requires chronic use of any parenteral or oral
             anticoagulation
Clinical trial NCT02114151 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: simeprevir, sofosbuvir
SMILES: [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Hepatitis C virus (HCV) genotype 1 infection (confirmed at screening).

          -  HCV ribonucleic acid (RNA) greater than 10,000 IU/mL at screening

          -  Treatment-experienced participants must have at least 1 documented previous course of
             interferon-based regimen with or without ribavirin

          -  Participants must have an hepatic imaging procedure (ultrasound, computerized
             tomography scan or magnetic resonance imaging scan) within 6 months prior to the
             screening visit (or between screening and Day 1) with no findings suspicious for
             hepatocellular carcinoma

          -  Participant must be willing and able to comply with the protocol requirements

          -  Participants with liver cirrhosis

        Exclusion Criteria:

          -  Evidence of clinical hepatic decompensation (history or current evidence of ascites,
             bleeding varices or hepatic encephalopathy)

          -  Infection/co-infection with HCV non-genotype 1

          -  Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2)
             (positive HIV-1 or HIV-2 antibodies test at screening)

          -  Co-infection with hepatitis B virus (hepatitis B-surface-antigen positive)

          -  Previously been treated with any direct acting anti-HCV agent (approved or
             investigational) for chronic HCV infection
Clinical trial NCT02114177 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: simeprevir, simeprevir, sofosbuvir, sofosbuvir
SMILES: [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Hepatitis C virus (HCV) genotype 1a or 1b infection confirmed before randomization

          -  Documentation of the presence or absence of a NS3 Q80K polymorphism in HCV genotype 1a
             infected participants before randomization

          -  Documentation of the IL28B genotype before randomization

          -  HCV ribonucleic acid level greater than 10,000 IU/mL at screening

          -  Treatment-experienced participants must have at least 1 documented previous course of
             interferon-based regimen with or without ribavirin

          -  Absence of cirrhosis in participants

        Exclusion Criteria:

          -  Evidence of clinical hepatic decompensation (history or current evidence of ascites,
             bleeding varices or hepatic encephalopathy)

          -  Infection/co-infection with HCV non-genotype 1a or 1b

          -  Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2)
             (positive HIV-1 or HIV-2 antibodies test at screening)

          -  Co-infection with hepatitis-B virus (hepatitis-B-surface-antigen positive)

          -  Previously been treated with any direct acting anti-HCV agent (approved or
             investigational) for chronic HCV infection
Clinical trial NCT02115750 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: etanercept, chs-0214
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults

          -  RA (Rheumatoid Arthritis) diagnosis for 6 months

          -  On stable dose of MTX of 8mg to 25mg per week

          -  Active disease: greater than 6 tender joints, greater than 6 swollen joints,
             C-reactive protein (CRP) greater than or equal to 0.5mg/dL, and disease activity score
             (DAS) with 28 joints (DAS28-CRP(4)) greater than or equal to 3.2

        Exclusion Criteria:

          -  Use of prednisone greater than 10mg/day

          -  Use of greater than one non-steroidal anti-inflammatory drug (NSAID)

          -  Use of biologic therapies for any cause

          -  Chemistry and hematology values outside protocol specified range

          -  Positive QuantiFERON-tuberculosis (TB) Gold Test

          -  Evidence of active lung disease on chest x-ray

          -  Major systemic infections

          -  Presence of significant comorbid conditions

          -  Known allergy to latex

          -  Women who are pregnant or nursing
Clinical trial NCT02116530 (phase 3, status: completed)
Conditions: hematopoietic/lymphoid cancer, nausea and vomiting, unspecified adult solid tumor, protocol specific
ICD codes: C96.9, D47.9, C96.Z, D47.Z9, Z80.7, Z85.79, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: olanzapine, chemotherapy (cisplatin or cyclophosphamide and doxorubicin), antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        -  Diagnosis of malignant disease

          -  No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing
             regimen or anthracycline + cyclophosphamide [AC])

               -  Cisplatin at a dose of ≥70mg/m^2, with or without other chemotherapy agent(s) OR

               -  Anthracycline (60 mg/m^2) plus cyclophosphamide(600 mg/m^2)

          -  Age ≥18 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2

          -  Required Initial Laboratory Values ≤ 120 days prior to registration

               -  Serum Creatinine ≤2.0 mg/dL

               -  Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic
                  transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)

               -  Absolute neutrophil count (ANC) ≥1500/mm^3

          -  No nausea or vomiting ≤ 24 hours prior to registration

          -  Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women
             of childbearing potential only (per clinician discretion)

          -  No severe cognitive compromise

          -  No known history of CNS disease (e.g. brain metastases, seizure disorder)

          -  No treatment with another antipsychotic agent such as risperidone, quetiapine,
             clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned
             during protocol therapy

          -  No chronic phenothiazine administration as an antipsychotic agent (patients may
             receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)

          -  No concurrent use of amifostine

          -  No concurrent abdominal radiotherapy

          -  No concurrent use of quinolone antibiotic therapy

          -  No chronic alcoholism (as determined by the investigator)

          -  No known hypersensitivity to olanzapine

          -  No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial
             infarction within the previous six months.

          -  No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic
             agent)
Clinical trial NCT02117479 (phase 3, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: ruxolitinib, placebo, capecitabine
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    the study was terminated early based on the results of the planned interim analysis.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas.

          -  Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Received 1 prior chemotherapy regimen for advanced or metastatic disease (not
             including neoadjuvant and/or adjuvant therapy).

          -  ≥ 2 weeks elapsed from the completion of previous treatment regimen and participants
             must have recovered or be at a new stable baseline from any related toxicities.

          -  Radiographically measurable or evaluable disease

          -  Modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

               1. mGPS of 1: C-reactive protein >10 mg/L and albumin ≥35 g/L

               2. mGPS of 2: C-reactive protein >10 mg/L and albumin <35 g/L

        Exclusion Criteria:

          -  Received more than 1 prior regimen for advanced or metastatic disease.

          -  Ongoing radiation therapy, radiation therapy administered within 30 days of
             enrollment.

          -  Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery,
             immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor
             embolization).

          -  Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase
             deficiency (DPD), or other known hypersensitivity to active substances, including
             fluorouracil (5-FU), or ruxolitinib, or any of their excipients.

          -  Prior treatment with a JAK inhibitor for any indication.
Clinical trial NCT02118766 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: an2728 topical ointment, 2%, matching vehicle control
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 2 years and older

          -  Has a clinical diagnosis of AD according to the criteria of Hanifin and Rajka

          -  Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)

          -  Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1

          -  All female subjects of childbearing potential must use acceptable methods of
             contraception from the Screening Visit continuously until 30 days after stopping study
             drug

        Exclusion Criteria:

          -  As determined by the study doctor, a medical history that may interfere with study
             objectives

          -  Unstable AD or any consistent requirement for high potency topical corticosteroids

          -  History of use of biologic therapy (including intravenous immunoglobulin)

          -  Recent or anticipated concomitant use of systemic or topical therapies that might
             alter the course of AD

          -  Recent or current participation in another research study

          -  Females who are breastfeeding, pregnant, or with plans to get pregnant during the
             participation in the study

          -  Participation in a previous AN2728 clinical trial
Clinical trial NCT02118792 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: an2728 topical ointment, 2%, matching vehicle control
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 2 years and older

          -  Has a clinical diagnosis of Atopic Dermatitis (AD) according to the criteria of
             Hanifin and Rajka

          -  Has AD involvement ≥ 5% Treatable %BSA (excluding the scalp)

          -  Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1

          -  All female subjects of childbearing potential must use acceptable methods of
             contraception from the Screening Visit continuously until 30 days after stopping study
             drug

        Exclusion Criteria:

          -  As determined by the study doctor, a medical history that may interfere with study
             objectives

          -  Unstable AD or any consistent requirement for high potency topical corticosteroids

          -  History of use of biologic therapy (including intravenous immunoglobulin)

          -  Recent or anticipated concomitant use of systemic or topical therapies that might
             alter the course of AD

          -  Recent or current participation in another research study

          -  Females who are breastfeeding, pregnant, or with plans to get pregnant during the
             participation in the study

          -  Participation in a previous AN2728 clinical trial
Clinical trial NCT02121717 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: chiglitazar, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);

          2. HbA1c≥ 7.5% and ≤ 10.0% after control of diet and exercises;

          3. Male and female,age between 18 and 70 years;

          4. BMI between 18.5-35kg/m2;

          5. Willing to be assigned to any treatment arm and sign inform consent.

        Exclusion Criteria:

          1. Type 1 diabetes;

          2. Treated by oral or injective antidiabetic drug before screening, including insulin and
             herb;

          3. Fasting plasma glucose > 13.3 mmol/L (240 mg/dL);

          4. Resistant hypertension [blood pressure above the goal despite adherence to at least 3
             optimally dosed antihypertensive medications (including diuretic) of different
             classes,or blood pressure is controlled to below the goal by at least 4 different
             classes of drugs];

          5. Plasma triglyceride > 500 mg/dL (5.65 mmol/L);

          6. Is treating by fibrates;

          7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic
             acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic
             nephropathy and diabetic neuropathy;

          8. Had transient ischemic attack,cerebrovascular accident or unstable angina in the past
             6 months;

          9. History of myocardial infarction or had conducted coronary angioplasty or coronary
             artery bypass graft surgery;

         10. Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy
             indicated by ECG;

         11. Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase
             or alanine aminotransferase > 2.5 fold of the upper limit of the normal range;

         12. Kidney diseases or serum creatinine exceed the normal range: male > 133 μmol/L or
             female >108 μmol/L;

         13. Had malignancy in the past 5 years, not including basal cell carcinoma;

         14. Had or is currently receiving treatment that can alter blood glucose metabolism,
             including but not limited to diuretic,hormone (corticotropin or steroids),beta
             blockers;

         15. Have the diseases that can alter blood glucose metabolism, including but not limited
             to active hepatitis, hyperthyroidism,or adrenal tumors;

         16. Edema with unknown reason;

         17. Alcohol or drug addiction;

         18. Had participated other drugs' clinical trials in the 3 months before screening;

         19. Pregnant or lactic women; or women of childbearing age who are not able to or is not
             willing to conduct contraception;

         20. Any condition that make investigator consider the subject is not suitable to
             participate the trial.
Clinical trial NCT02122471 (phase 3, status: completed)
Conditions: chronic idiopathic constipation
ICD codes: K59.04
Drugs: plecanatide, placebo
SMILES: [H][C@](C)(O)[C@]1([H])N=C(O)[C@]2([H])CSSC[C@]([H])(N=C(O)[C@]([H])(CCC(O)=O)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@@]([H])(N)CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CN=C1O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(C)C(O)=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18-80, inclusive

          -  Meets modified Rome III criteria for functional chronic idiopathic constipation for at
             least 3 months with symptom onset for at least 6 months

          -  Completed a colonoscopy in accordance with American Gastroenterological Association
             (AGA) colon cancer screening guidelines (5 years), with no clinically significant
             findings

          -  Willing to maintain a stable diet during the study

        Exclusion Criteria:

          -  Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any
             laxative or prohibited medicine for > 25% of Bowel Movements (BMs) during the 3 months
             prior to screening visit OR during the 14 day pre-treatment assessment

          -  Active peptic ulcer disease, diabetes or hypertension not adequately treated or not
             stable

          -  History of cathartic colon, laxative, enema abuse, or ischemic colitis

          -  Fecal impaction within 3 months of screening

          -  Patient has had /has any: diseases or conditions associated with constipation (GI or
             CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor
             dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal
             fissures or any disease or condition that can affect GI motility or defecation or can
             be associated with abdominal pain

          -  Unexplained and clinically significant "alarm symptoms" including lower GI bleeding,
             iron-deficiency anemia, weight loss or systemic signs of infection or colitis

          -  Major surgery, stroke or myocardial infarction (MI) within 60 days of screening

          -  Participated in a previous plecanatide clinical trial
Clinical trial NCT02123654 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: daclatasvir, asunaprevir, dcv 3daa
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Males and females, ≥ 20 years of age

          -  Subjects chronically infected with HCV GT-1

          -  HCV RNA viral load of ≥ 100,000 IU/mL

        Exclusion Criteria:

          -  Hepatocellular carcinoma

          -  Co-infection with Hepatitis B virus (HBV) or Human immunodeficiency virus (HIV)

          -  Severe or uncontrollable complication
Clinical trial NCT02125409 (phase 3, status: unknown status)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: acetylsalicylic acid
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Men and women, aged ≥ 18 and ≤ 69.

          2. Patients should have an indication for screening colonoscopy

               1. First degree relative of patient with CRC.

               2. Personal history of adenomas.

               3. People older than 50 and FOBT positive

          3. Routine hematological and biochemical parameters within the normal range.

        Exclusion Criteria:

          1. Allergy to ASA or other NSAIDs.

          2. Previous use of ASA, NSAIDS, antiplatelet agents, corticosteroids or misoprostol in
             the previous 15 days and/or anticipated need for these drugs during the study period.

          3. Peptic ulcer history or any other gastrointestinal disease that could be considered a
             contraindication for ASA use without the concomitant use of a proton-pump inhibitor.

          4. Subjects with coagulation disorder or serious comorbid condition.

          5. Malignancies, excluding CRC, diagnosed in the previous 5 years

          6. Cigarette smoking, history of drug or alcohol abuse

          7. Pregnant women or breast feeding
Clinical trial NCT02126358 (phase 3, status: completed)
Conditions: type 2 diabetes, dyslipidemia
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: gemigliptin and/or rosuvastatin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus with Dyslipidemia

          -  Adults who are at least 19 years old

        Exclusion Criteria:

          -  Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma

          -  Patients with gestational diabetes or secondary diabetes

          -  Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring
             treatment

          -  Patients with thyroid gland dysfunction deviating from the normal TSH range

          -  Patients with pituitary insufficiency or adrenal insufficiency